Actinium Pharmaceuticals Appoints Corey Sohmer As Vice President Of Finance And Business Development
NEW YORK, Sept. 18, 2013 /PRNewswire/ — Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) («Actinium» or «the Company»), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the appointment of Corey Sohmer to the position of Vice President of Finance and Business Development. Mr. Sohmer will be responsible for directing Actinium’s accounting, finance and investor relations functions as well as supporting capital raising and business development activities.
«Corey has a broad financial background in the biotech industry. He brings leadership experience relevant to all key aspects of Actinium’s corporate development, including financing, accounting, investor relations and public reporting," said Kaushik J. Dave, Ph. D., MBA, President and CEO of Actinium. «Corey will be an extremely valuable addition to the Actinium team as we continue to progress the Company’s lead candidates
«I am excited to join the Company at a pivotal point in its growth and look forward to contributing to its future success," said Mr. Sohmer. Prior to joining Actinium, Mr. Sohmer served in a variety of core finance and business development functions over the span of twelve years at three NASDAQ listed biopharmaceutical companies. Most recently, Mr. Sohmer was the Director Corporate Finance at Cyclacel Pharmaceuticals, Inc. for six years. Before joining Cyclacel, he was the Senior Director of Financial Planning and External Reporting at EpiCept Corporation and Manager of Finance and Business Development at Pharmos Corporation. He has more than 20 years of finance and accounting experience. Mr. Sohmer holds a Masters in Business Administration and a Bachelors of Science degree in Accounting from Bentley University.